💡NEW study by Spencer S Watson Johanna Joyce et al., in Nature Communications
🧠Glioblastoma vs. brain metastasis show unique responses to radiation therapy 🩻

Ludwig Cancer Université de Lausanne CHUV / Centre hospitalier universitaire vaudois Johanna Joyce Lab
➡️ #OpenAccess : rdcu.be/dELus

Most patients diagnosed with glioblastoma die within a year, so innovative therapeutic strategies are needed. An editorial describes the science behind one strategy using a secreting chimeric antigen receptor (CAR) T cell. Read the full editorial: nej.md/49yGoKf

Out now: CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T cell pool by Paulien Kaptein @Thommen_ds in Cancer Discovery #publicationoftheweek ⬇️ bit.ly/3JdKjkM

Researchers Thijn Brummelkamp, Bernards Laboratory@NKI, and The Agami Lab from the NKI and Oncode Institute will each be awarded a prestigious European Research Council (ERC) Advanced Grant today. This will allow them to deepen their innovative and often surprising research ideas ➡️ bit.ly/4aMY4mi

🚨Fantastic pair of papers in nature today from Evan Weber, Mackall Lab and the Darcy lab Peter Mac Cancer Centre on enforcing stem-like molecular programs in therapeutic T cells through overexpression of #FOXO1 ! 👇
nature.com/articles/s4158…. Children's Hospital Stanford Cancer Institute Parker Institute for Cancer Immunotherapy

📰 Simultaneous publication #AACR24 :
Ph1 study of CTX130 (allogeneic anti-CD70 CAR-T with TRAC, β2M and CD70 disruptions) in advanced ccRCC.

➡️ Safe
➡️ n=16; overall DCR incl. SD = 81% (n=1 with CR)

Watching the space for CTX131 with ⬆️ persistence.

aacrjournals.org/cancerdiscover…

Incredibly proud of our Melanoma and Cell Therapy teams at Stanford Cancer Institute. We performed the first commercial lifileucel (AMTAGVI) infusion this afternoon. We are so excited to bring this treatment for advanced melanoma to our patients! #CellTherapy #TIL (posted with consent)

Saturday afternoon read between Premier League games: nice tweetorial by the inimitable Charles Swanton about a new study in Cancer Discovery about spatial organisation of lung cancer TME in the context of tumour immunogenicity and cancer evolution. Congrats Swanton /TRACERx team!…

This evening, the 30 members of the 2024 class of AACR Fellows were inducted into the AACR Academy. The distinguished scientists who comprise the AACR Academy serve as a global brain trust, providing scientific leadership to advance the AACR's mission. #AACR24

🧪 All you need to know about the state of play of cell therapy in solid cancers - Fantastic tour de force talk by Sebastian Klobuch AACR #AACR24 on advances in TILs & modified-TCR therapies.

Also check out the latest review by Sebastian Klobuch & colleagues The Netherlands Cancer Institute 👇
nature.com/articles/s4157…

Are you attending AACR #AACR24 on in San Diego 🇺🇸 this week?

Our Special Issue ‘Developments in Cell Therapy’ Editor - Sebastian Klobuch is here!

Looking forward to discussing your work.

A truly deserved 🏅AACR Award for Lifetime Achievement in Cancer Research #AACR24 . Congratulations Dr. Steven Rosenberg National Cancer Institute!

Incredible & heartwarming award lecture summarising >40 years of work - relentlessly pushing the boundaries of immunotherapy! Truly inspirational.

I'm just going to place this here with the hopes of seeing you there to discuss and discover #Bridge24 Paolo A. Ascierto leads, we follow #worktodo #immunotherapy
melanomabridge.org

Reinvigoration of dysfunctional T cells in cancer using CD8-targeted IL2
doi.org/10.1158/2159-8…
doi.org/10.1158/2159-8…

We're proud to welcome prof. dr. Rene Medema as our new Chief Scientific Officer this week 🧡 He brings more than 10 years of executive experience Antoni van Leeuwenhoek and The Netherlands Cancer Institute. In addition to his role as CSO, he will keep leading his research group. Read more: prinsesmaximacentrum.nl/en/news-events…

Out in JAMA huge academic effort to clarify role of #TILs tumor-infiltrating lymphocytes to avoid #chemotherapy in some patients with triple-negative #BreastCancer : honored & grateful to have Università di Genova Ospedale San Martino Genova part of it!
OncoAlert #bcsm

jamanetwork.com/journals/jama/…

Ph II trial of TIL therapy (Lifileucel) in Adv NSCLC post IO+/-chemo:

- Pre-conditioning chemo (cyclophos/fludara)➡️TIL➡️IL2
- ORR 21.4% (6/28)
- In 60% cases, TIL from lung mets
- 2 tx-related deaths

⁦⁦Adam J. Schoenfeld⁩ ⁦OncoAlert⁩ #LCSM aacrjournals.org/cancerdiscover…

The first clinical trial using a mRNA-nanoparticle to deliver a protein replacement, which gets into liver cells and restores mitochondrial function. For a life-threatening, ultra-rare disease that has no treatment.
New nature, with results in 16 patients
nature.com/articles/s4158…

What surprises these 3 rockstars are preparing for us at ESMO - Eur. Oncology #MAP2024 in London?

lisaderosa Mariam Jamal-Hanjani Joaquin Mateo

esmo.org/meeting-calend…
-------------

FabriceAndre Charles Swanton John Haanen